Losartan Potassium Tablets Recalled Due to Nitrosamine Impurity
Pharma Pac is recalling Losartan Potassium 100 mg tablets because traces of a nitrosamine impurity were found in the active ingredient.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the presence of a nitrosamine impurity which is a potential carcinogen.
Plain-English summary
H J Harkins Company Inc dba Pharma Pac is recalling Losartan Potassium 100 mg tablets. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) impurity in the Active Pharmaceutical Ingredient (API).
The affected product consists of white to off-white, film-coated, tear-drop shaped tablets debossed with "H" on one side and "145" on the other. The specific lot numbers involved are Pharma Pac Lot # LTO00EW (Exp. 11/19) and MFG Lot # LOP17087 (Exp. 11/2019). The NDC numbers are 76519-1033-03 and 31722-0702-30.
The product was distributed to a physician's office in California. Patients who have received this medication should consult their healthcare provider for guidance on alternative treatments or further instructions.
The recalled product
- Product
- Losartan Potassium 100 mg Tablets # 30 Losartan potassium tablets USP, 100 mg are white to off white, film coated, tear drop shaped tablets, debossed with "H" on one side and "145" on the other side.
- Manufacturer
- H J Harkins Company Inc dba Pharma Pac
- Category
- Drug — Prescription Medication
- Affected units
- 300
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Pharma Pac NDC: 76519-1033-03
- Pharma Pac Lot # LTO00EW
- Exp. 11/19
- MFG NDC 31722-0702-30
- MFG Lot # LOP17087
- Exp. 11/2019.
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · H J Harkins Company Inc dba Pharma Pac
See all →- ModerateFDA Recalls Acetaminophen and Codeine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2020-04-22
- HighAcetaminophen Tablets Recalled Due to Foreign Tablet Contamination
FDA (Drugs) · 2020-03-18
- SevereRanitidine Tablets Recalled Due to NDMA Impurity Detection
FDA (Drugs) · 2020-01-29
- ModeratePharma Pac Recalls Neomycin Ophthalmic Ointment for Quality Control Issues
FDA (Drugs) · 2019-08-07
- SevereDiphenhydramine Liquid Recalled for Potential Microbial Contamination
FDA (Drugs) · 2019-07-03
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08